FDA Announces Joint Meeting of Psychopharmacologic Drugs and Drug Safety Committees, Requests Public Comments

Summary

The US Food and Drug Administration (FDA) is hosting a joint meeting of its Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, inviting the public to attend and submit comments on the agenda items, which will be made available in a public docket.